PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data-Reference-Cited by-同舟云学术

PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data

Published:2019-03 Issue: Volume:129 Page:41-47
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Koh Young Wha^ORCID,Lee Su Jin,Han Jae-Ho,Haam Seokjin^ORCID,Jung Joonho,Lee Hyun Woo

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference48 articles.

1. Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade;Weber;Semin. Oncol.,2010

2. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N. Engl. J. Med.,2015

3. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer;Gettinger;J. Clin. Oncol.,2016

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer;Shukuya;J. Thorac. Oncol.,2016

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents;Frontiers in Pharmacology;2024-08-05

2. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities;Current Oncology;2024-07-01

3. MicroRNA-561-3p indirectly regulates the PD-L1 expression by targeting ZEB1, HIF1A, and MYC genes in breast cancer;Scientific Reports;2024-03-10

4. From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer;Frontiers in Immunology;2024-02-15

5. Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic Agents;2024-01-25